Please login to the form below

Not currently logged in
Email:
Password:

Biogen’s corporate affairs SVP joins Sanofi

Kathleen Tregoning becomes executive vice president, external affairs

Sanofi Kathleen TregoningSanofi has appointed Kathleen Tregoning as executive vice president for external affairs.

Tregoning will join the Paris, France headquartered company from 27 February, when she will take responsibility for its market access, public affairs, government affairs, corporate communications, global policy and corporate social responsibility operations.

She brings over 20 years of policy, advocacy, stakeholder outreach and external engagement experience to the role, most recently from Biogen where she was senior vice president of corporate affairs.

Prior to this, Tregoning was vice president of Biogen's public policy and government affairs, having moved to the biotech in 2006 from her healthcare policy position in the United States Senate and United States House of Representatives.

Olivier Brandicourt, chief executive at Sanofi, said: “Kathleen brings a unique set of talents and experience to Sanofi that combines a deep political and policy expertise with highly relevant corporate experience in the biopharmaceutical industry.

"Working closely with the entire executive leadership team, Kathleen will lead our efforts to drive a better understanding of the value of our innovations among external stakeholders and ensure appropriate market access for our various healthcare offerings.”

30th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics